Kymera Therapeutics, Inc. (KYMR): EBITDA
-$341.09M
Year ended 2025-12-31
-$341.95M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$341.09M | n/m | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | -$254.26M | n/m | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | -$161.97M | n/m | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | -$158.28M | n/m | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | -$98.13M | n/m | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | -$44.54M | n/m | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | -$41.38M | n/a | 2022-02-24, From 2019-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | -$341.09M | n/m |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | -$117.28M | n/m |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | -$113.26M | n/m |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | -$85.61M | n/m |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | -$50.68M | n/m |
| Scilex Holding Co (SCLX) | 2025-12-31 | -$341.38M | n/m |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $237.0K | -96.2% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | -$467.65M | n/m |
| Alector, Inc. (ALEC) | 2025-12-31 | -$150.29M | n/m |
Compare KYMR, SGMOQ, CCCC, XFOR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗